Fumadi Prolonged-release Capsule
Dimethyl fumarate
240 mg
Macleods Pharmaceuticals Ltd.
| Pack size | 60's Pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 48.54 AED |
Available as:
Indications
Fumadi Prolonged-release Capsule is used for:
Used in multiple sclerosis patients with relapsing forms.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Dimethyl fumarate :
Mechanism of Action
The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF). MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. As well MMF is an agonist at the nicotinic acid receptor, but the relevance of this is not known.
Note
Fumadi 240 mg Prolonged-release Capsule manufactured by Macleods Pharmaceuticals Ltd.. Its generic name is Dimethyl fumarate. Fumadi is availble in Saudi Arabia.
Farmaco SA drug index information on Fumadi Prolonged-release Capsule is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.
Some other brands of Dimethyl fumarate :
Capsule
TECFIDERA
240 mg
BAXTER COMPANY LIMITED
Capsule
TECFIDERA
120 mg
BAXTER COMPANY LIMITED
Gastro-resistant Capsule, Hard
SCLERA
120 mg
HIKMA PHARMACEUTICALS LLC
Gastro-resistant Capsule, Hard
SCLERA
240 mg
Hikma Pharmaceuticals
Delayed-release Capsule
DEFRA
120 mg
Macleods Pharmaceuticals Ltd.